 |
 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
E-Mail
ShareOther Antiretrovirals in Development
See also: HIV Drugs in Development
Other Drugs
- Gilead Sciences, Tibotec to Develop Second Once-Daily HIV Treatment (July 17, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Acyclovir: The Next New HIV Drug? (February 10, 2009)
From Project Inform - High-Dose Intravenous Immunoglobulin May Reduce Latent HIV Reservoir in Resting CD4+ Cells, Study Suggests (February 10, 2009)
A five-day course of high-dose intravenous immunoglobulin appears to somehow activate replication-competent HIV in the resting CD4+ cells of patients on HAART, ultimately leading to a reduction in those patients' latent HIV reservoirs, according to the results of a nine-patient study presented by Magnus Gisslén, M.D., Ph.D.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Biotechnology Company to Launch Trial of New HIV/AIDS Treatment That Would Target DNA (February 4, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Experimental Treatment Lengthens Lifespan of Monkeys With Simian Version of HIV, Study Says (December 12, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Existing Anti-Obesity Drugs May Be Effective Against Flu, Hepatitis and HIV (September 29, 2008)
From University of Rochester Medical Center - Suppression of Human Protein Reduces HIV's Ability to Enter T Cells, Replicate, Study Finds (April 30, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Not Your Everyday Antiretroviral: KP-1461, an HIV DNA Killer (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News - Peptide Found in Human Blood Inhibits 60 Strains of HIV, Study Says (April 20, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis